No photo of Barbara Pro

View Scopus Profile

Barbara Pro

  • 8068 Citations
20002021
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Clinical trials

Training Experience

1995Internship, Mount Sinai Hospital, New York
1996Residency, Mount Sinai Hospital, New York

Education/Academic qualification

MD, University La Sapienza, Rome, Italy

… → 1988

Research interests

  • Blood Cancer (leukemia and lymphomas)
  • Clinical Research

Fingerprint Dive into the research topics where Barbara Pro is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 15 Similar Profiles
Peripheral T-Cell Lymphoma Medicine & Life Sciences
Non-Hodgkin's Lymphoma Medicine & Life Sciences
Lymphoma Medicine & Life Sciences
Hodgkin Disease Medicine & Life Sciences
T-Cell Lymphoma Medicine & Life Sciences
Mantle-Cell Lymphoma Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences
Follicular Lymphoma Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2006 2021

Prot #VS-0145-225: A Muti-Center, Phase 2, Open Label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Pro, B.

Parexel, Verastem, Inc.

8/6/18 → 8/6/21

Project: Research project

Prot #APL-B-021-13: A Phase II Study of Plitidepsin in Patients with Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma

Pro, B.

Pharma Mar, S.A. Sociedad Unipersonal

2/28/17 → 2/28/20

Project: Research project

Prot #X16042: A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients with MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen

Pro, B.

Millennium Pharmaceuticals, Inc

6/1/15 → 6/1/21

Project: Research project

Prot #RV-CL-PTCL-PI-003974: NU 14H04: Phase II Study of Romidepsin Plus Lenalidomide for Patients with Previously Untreated PTCL

Pro, B.

Celgene Corporation

5/14/15 → 5/14/21

Project: Research project

Prot #BO29337: A Phase II, Open-Label Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine Plus Rituximab (BR) in Comparison with BR Alone or GDC-0199 Plus Rituximab (R) in Patients with Relapsed and Refractory Follicular Non-H

Pro, B.

Covance Inc., Genentech, Inc.

4/10/15 → 4/30/20

Project: Research project

Research Output 2000 2019

35 Citations (Scopus)

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

ECHELON-2 Study Group, Jan 19 2019, In : The Lancet. 393, 10168, p. 229-240 12 p.

Research output: Contribution to journal › Article

Peripheral T-Cell Lymphoma
Drug Therapy
Vincristine
Prednisone
Doxorubicin

Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma

Khashab, T., Hagemeister, F., Romaguera, J. E., Fanale, M. A., Pro, B., McLaughlin, P., Rodriguez, M. A., Neelapu, S. S., Fayad, L., Younes, A., Feng, L., Vega, F., Kwak, L. W. & Samaniego, F., May 1 2019, In : British Journal of Haematology. 185, 4, p. 670-678 9 p.

Research output: Contribution to journal › Article

Pentostatin
Non-Hodgkin's Lymphoma
Cyclophosphamide
Disease-Free Survival
Survival Rate
1 Citation (Scopus)

Novel therapies and approaches to relapsed/refractory HL beyond chemotherapy

Mina, A. A., Vakkalagadda, C. & Pro, B., Mar 2019, In : Cancers. 11, 3, 421.

Research output: Contribution to journal › Review article

Open Access
Hodgkin Disease
Salvage Therapy
Drug Therapy
Stem Cells
Transplants

Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry

Lansigan, F., Horwitz, S. M., Pinter-Brown, L. C., Rosen, S. T., Pro, B., Hsi, E. D., Federico, M., Gisselbrecht, C., Schwartz, M., Bellm, L. A., Acosta, M., Shustov, A. R., Advani, R. H., Feldman, T., Lechowicz, M. J., Smith, S. M., Tulpule, A., Craig, M. D., Greer, J. P., Kahl, B. S. & 5 others, Leach, J. W., Morganstein, N., Casulo, C., Park, S. I. & Foss, F. M., Jan 1 2019, In : Acta Haematologica.

Research output: Contribution to journal › Article

Peripheral T-Cell Lymphoma
Registries
Therapeutics
Survival
T-Cell Lymphoma
1 Citation (Scopus)

Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry

Stuver, R. N., Khan, N., Schwartz, M., Acosta, M., Federico, M., Gisselbrecht, C., Horwitz, S. M., Lansigan, F., Pinter-Brown, L. C., Pro, B., Shustov, A. R., Foss, F. M. & Jain, S., Jun 1 2019, In : American Journal of Hematology. 94, 6, p. 641-649 9 p.

Research output: Contribution to journal › Article

Peripheral T-Cell Lymphoma
Combination Drug Therapy
Registries
Retreatment
Therapeutics